^
Association details:
| Biomarker: | CLDN1 positive |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | ALE.C04 (CLDN1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC
Published date:
08/24/2023
Excerpt:
Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that the US Food and Drug Administration (FDA) has granted Fast Track development program for ALE.C04 for the treatment of patients with recurrent or metastatic, CLDN1-positive HNSCC.